Disclose Contact Information Sample Clauses

Disclose Contact Information. Make known to any person the names and addresses, or other contact information, of any of the customers, suppliers, or other persons having significant business relationships with the Company within the information technology industry, so that such person could affect, or attempt to affect, any of those relationships to the detriment of the Company; or
AutoNDA by SimpleDocs
Disclose Contact Information. Make known to any person the names and addresses, or other contact information, of any of the customers, suppliers, or other persons having significant business relationships with LifeCare within the health care industry, so that such person could affect, or attempt to affect, any of those relationships to the detriment of LifeCare; or
Disclose Contact Information. Make known to any person the names and addresses, or other contact information, of any of the customers, suppliers, or other persons having significant business relationships with the Company within the health care industry, so that such person could affect, or attempt to affect, any of those relationships to the detriment of the Company; or

Related to Disclose Contact Information

  • Contact Information Following are the Mxxxxx Sxxxxxx departments involved in servicing the Funds and the corresponding contact information. Abbreviation Department Primary Contact Telephone E-mail Futures Desk MSC Futures Trading Desk Bxxxx Xxxxxxx Dxxxxx Xxxxxxxxx 212.761.1782 212.761.2248 Bxxxx.Xxxxxxx@xxxxxxxxxxxxx.xxx Dxxxxx.Xxxxxxxxx@xxxxxxxxxxxxx.xxx Futures Ops MSC Futures Operations Sxxxx Xxxxxxx Exxx Xxxxx 212.276.0477 212.276.0578 Sxxxx.Xxxxxxx@xxxxxxxxxxxxx.xxx Exxx.Xxxxx@xxxxxxxxxxxxx.xxx FX Desk MSC Foreign Exchange Trading Desk Mxxxxxx Xxxxxxx 212.761.2700 Mxxxxxx.Xxxxxxx@xxxxxxxxxxxxx.xxx FX Ops MSC Foreign Exchange Operations Jxxx Xxxxx 718.754.4868 Jxxx.Xxxxx@xxxxxxxxxxxxx.xxx MF Accounting Mxxxxx Sxxxxxx Managed Futures Accounting Jxx Xxxxxxxx Kxxxx Xxxxxx 917.790.5702 917.790.5701 Jxx.Xxxxxxxx@xxxxxxxxxxxxx.xxx Kxxxx.Xxxxxx@xxxxxxxxxxxxx.xxx MF Ops Mxxxxx Sxxxxxx Managed Futures Operations Lxxxx Xxxxx 212.905.2720 Lxxxx.Xxxxxxxxx@xxxxxxxxxxxx.xxx MF Prod Org Mxxxxx Sxxxxxx Managed Futures Product Origination Pxxxxxx Xxxx 212.905.2736 Pxxxxxx.Xxxx@xxxxxxxxxxxxx.xxx MF Strat Plan Mxxxxx Sxxxxxx Managed Futures Strategic Planning Cxxxx Xxxxx 212.905.2731 Cxxxx.Xxxxx@xxxxxxxxxxxxx.xxx FUND ACCOUNTS: Account Configuration · Futures and Futures Options Trading - For each CTA trading program three Fund trading accounts will be assigned. A MS&Co segregated account, prefix 052. A MS&Co secured account, prefix 05A. A MSIL non-regulated (by the CFTC) account, prefix 045. · FX (Non-Options) Trading - One Fund account for each CTA trading program will be assigned at MS&Co, prefix 058. · FX Options Trading – One Fund account for each CTA trading program will be assigned at MSCG (if needed), prefix 057. · Excess and FX Custody Accounts – For each CTA trading program two Fund accounts will be set up at MS&Co. One account will be designated as a custody account for MS&Co FX. MF Ops will maintain equity in the custody account sufficient to cover margin requirements of the FX trading account. The second account will contain the balance of excess equity that is not required in the custody and futures trading accounts. Statements · Futures – The CTA should contact Futures Ops regarding access to Fund futures account statements. · FX – The CTA should contact FX Ops regarding access to Fund FX account statements. · Excess and Custody – The CTA should contact MF Ops regarding access to the Fund account statements at MS&Co.

  • Product Information Galapagos recognizes that by reason of, inter alia, Xxxxxx’x status as an exclusive licensee pursuant to the grants under Section 5.2, Xxxxxx has an interest in Galapagos’ retention in confidence of certain information of Galapagos. Accordingly, during the Term, Galapagos shall, and shall cause its Affiliates and its and their respective officers, directors, employees, and agents to, keep completely confidential, and not publish or otherwise disclose, and not use directly or indirectly for any purpose other than to fulfill Galapagos’ obligations hereunder any Information owned or otherwise Controlled by Galapagos or any of its Affiliates specifically relating to any Licensed Compound or Licensed Product, or the Exploitation of any of the foregoing (the “Product Information”); except to the extent (x) the Product Information is in the public domain through no fault of Galapagos, its Affiliates or any of its or their respective officers, directors, employees, or agents; (y) such disclosure or use is expressly permitted under Section 9.3, or (z) such disclosure or use is otherwise expressly permitted by the terms of this Agreement. For purposes of Section 9.3, Xxxxxx shall be deemed to be the disclosing Party with respect to Product Information under Section 9.3 and Galapagos shall be deemed to be the receiving Party with respect thereto. For further clarification, (i) without limiting this Section 9.1, to the extent Product Information is disclosed by Galapagos to Xxxxxx pursuant to this Agreement, such information shall, subject to the other terms and conditions of this Article 9, also constitute Confidential Information of Galapagos with respect to the use and disclosure of such Information by Galapagos (and Galapagos shall be deemed to be the disclosing Party with respect to Product Information under Section 9.3 and Xxxxxx shall be deemed to be the receiving Party with respect thereto), but (ii) the disclosure by Galapagos to Xxxxxx of Product Information shall not cause such information to cease to be subject to the provisions of this Section 9.1 with respect to the use and disclosure of such Confidential Information by Galapagos. If this Agreement is terminated in its entirety or with respect to the Terminated Territory, this Section 9.1 shall have no continuing force or effect with respect to the use or disclosure of such information solely in connection with the Exploitation of the Licensed Compound or Licensed Product for the benefit of the Terminated Territory, but the Product Information, to the extent disclosed by Xxxxxx to Galapagos hereunder, shall continue to be Confidential Information of Xxxxxx, subject to the terms of Sections 9.2, 9.3, and 9.7 for purposes of the surviving provisions of this Agreement.

  • Corporate Information Promptly upon, and in any event within five (5) Business Days after, becoming aware of any additional corporate or limited liability company information or division information of the type delivered pursuant to Section 6.01(f), or of any change to such information delivered on or prior to the Closing Date or pursuant to this Section 8.01 or otherwise under the Credit Documents, a certificate, certified to the extent of any change from a prior certification, from the secretary, assistant secretary, managing member or general partner of such Credit Party notifying the Administrative Agent of such information or change and attaching thereto any relevant documentation in connection therewith.

  • Information Confidential As partial consideration for the granting of the Award hereunder, you hereby agree to keep confidential all information and knowledge, except that which has been disclosed in any public filings required by law, that you have relating to the terms and conditions of this Agreement; provided, however, that such information may be disclosed as required by law and may be given in confidence to your spouse and tax and financial advisors. In the event any breach of this promise comes to the attention of the Company, it shall take into consideration that breach in determining whether to recommend the grant of any future similar award to you, as a factor weighing against the advisability of granting any such future award to you.

  • Information The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities which have been requested by the Buyer or its advisors. The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, afforded the opportunity to ask questions of the Company. Notwithstanding the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer. Neither such inquiries nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect Buyer’s right to rely on the Company’s representations and warranties contained in Section 3 below. The Buyer understands that its investment in the Securities involves a significant degree of risk. The Buyer is not aware of any facts that may constitute a breach of any of the Company's representations and warranties made herein.

  • PROCESS INFORMATION Describe planned use, and include brief description of manufacturing processes employed.

  • Member Information Within five (5) days after receipt of a request from the Company, the Investor agrees to provide such information with respect to its status as a member (or potential member) of the Company and to execute and deliver such documents as may reasonably be necessary to comply with any and all laws and regulations to which the Company is or may become subject, including, without limitation, the need to determine the accredited investor status of the Company’s members. If the Investor transfers any Units, it will require the transferee of such Units to agree to provide such information to the Company requires as a condition of such transfer.

  • Information Updates During the term of this Agreement the Trust shall have the ongoing obligation to provide UMBFS with the following documents as soon as they become effective: (i) certified copies of all amendments to its Declaration of Trust and By-laws made after the date of this Agreement; and (ii) a copy of each Fund’s currently effective Prospectus. For purposes of this Agreement, UMBFS shall not be deemed to have notice of any information contained in any such Prospectus until a reasonable time after it is actually received by UMBFS.

  • Information Reporting (a) The Fund agrees that, during the Current Special Rate Period and so long as BANA or any Affiliate thereof is the beneficial owner of any Outstanding VRDP Shares, it will deliver, or direct the Tender and Paying Agent to deliver, to BANA and any such Affiliate:

  • Transaction Information The Adviser shall furnish to the Trust such information concerning portfolio transactions as may be necessary to enable the Trust or its designated agent to perform such compliance testing on the Funds and the Adviser’s services as the Trust may, in its sole discretion, determine to be appropriate. The provision of such information by the Adviser to the Trust or its designated agent in no way relieves the Adviser of its own responsibilities under this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.